Effects of a reversible β-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses

Clinical and Experimental Allergy

Volumn 36, Issue 4, 2006, Pages 458-464

  Erin, E M ^a   Leaker, B R ^a   Zacharasiewicz, A ^b   Higgins, L A ^a   Nicholson, G C ^a   Boyce, M J ^c   De Boer, P ^d   Jones, R C ^d   Durham, S R ^b   Barnes, P J ^b   Hansel, T T ^a,e  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^d RW Johnson Pharmaceutical Research   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

tryptase trypsin inhibitor; Allergen challenge; Allergic rhinitis; Nasal lavage

Indexed keywords

ALLERGEN; BUDESONIDE; CHEMOKINE; CYTOKINE; INTERLEUKIN 5; PLACEBO; RWJ 58643; TRYPSIN INHIBITOR; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ALLERGY; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; EOSINOPHILIA; GRASS POLLEN; HUMAN; HUMAN CELL; IMMUNOASSAY; INFLAMMATION; LOW DRUG DOSE; MALE; MEDIATOR; NEUTROPHIL CHEMOTAXIS; NOSE ALLERGY; NOSE MUCUS; OPEN STUDY; OUTCOME ASSESSMENT; PHLEUM PRATENSE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYMPTOM;

ADMINISTRATION, INTRANASAL; ADULT; ALLERGENS; BENZOTHIAZOLES; BUDESONIDE; CHEMOKINE CCL2; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-5; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MAST CELLS; MIDDLE AGED; PYRROLIDINES; RHINITIS, ALLERGIC, SEASONAL; SERINE ENDOPEPTIDASES; THIAZOLES; TRYPSIN INHIBITORS; TRYPTASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645305985     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02474.x     Document Type: Article

References (34)

1. Kay AB. Allergy and allergic diseases second of two parts. N Engl J Med 2001 344 109 13.
2. Davies DE Wicks J Powell RM Puddicombe SM Holgate ST. Airway remodeling in asthma new insights. J Allergy Clin Immunol 2003 111 215 25.
3. Cocks TM Moffatt JD. Protease-activated receptor-2 (PAR2) in the airways. Pulm Pharmacol Ther 2001 14 183 91.
4. Cocks TM Moffatt JD. Protease-activated receptors sentries for inflammation? Trends Pharmacol Sci 2000 21 103 8.
5. Sommerhoff CP. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 2001 164 S52 8.
6. Schwartz LB Irani A Roller K Castells MC Schechter N. Quantitation of histamine,tryptase,and chymase in dispersed human T and TC mast cells. J Immunol 1987 138 2611.
7. Lan RS Stewart GA Henry PJ. Role of protease-activated receptors in airways function: a target for therapeutic intervention. Pharmacol Ther 2002 95 239-57.
8. Abraham WM. Tryptase potential role in airway inflammation and remodling. Am J Physiol Lung Cell Mol Physiol 2002 282 193 6.
9. Ruoss SJ Hartmann T Caughey GH. Mast cell tryptase is a mitogen for cultued fibroblasts. J Clin Invest 1991 88 493 9.
10. Brown JK Jones CA Rooney LA Caughey GH Hall IP. Tryptase's potent mitogenic effects in human airway smooth muscle cells are via nonproteolytic actions. Am J Physiol Lung Cell Mol Physiol 2002 282 L197 206.
11. Cairns JA Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996 156 275 83.
12. He S Walls AF. Human mast cell tryptase a stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol 1995 328 89 97.
13. Wright CD Havill AM Middleton SC et al. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3- carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). Biochem Pharmacol 1999 58 1989 96.
14. Sylvin H Dahlback M Van Der Ploeg I Alving K. The tryptase inhibitor APC-366 reduces the acute airway response in pigs sensitized to Ascaris suum. Clin Exp Allergy 2002 31 967 71.
15. Krishna MT Chauhan A Little L et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001 107 1039 45.
16. Clark J Van Dyke RE Kurth MC. Tryptase Inhibitors. In Hansel TT Barnes PJ eds. New drugs for asthma, allergy and COPD. Basel Karger 2001 170 2.
17. D'Andrea MR Derian CK Leturcq D et al. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. Histochem Cytochem 1998 46 157 64.
18. Barrios VE Jarosinski MA Wright CD. Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi. Biochem Pharmacol 2003 66 519 25.
19. Cocks TM Fong B Chow JM et al. A protective role for protease-activated receptors in the airways. Nature 1999 398 156 60.
20. Molino M Woolkalis MJ Reavey-Cantwell J et al. Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J Biol Chem 1997 272 11133 41.
21. Schmidlin F Amadesi S Dabbagh K et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002 169 5315 21.
22. Costanzo M J Yabut S C Almond H R et al. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic actions of a dipeptide-based transition-state analogue containing a benzothiazole ketone. J Med Chem 2003 46 3865 76.
23. Terada N Hamano N Kim WJ et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001 164 575 9.
24. Greiff L Petersen H Mattsson E et al. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. Clin Exp Allergy 2001 31 1321 7.
25. Sim TC Grant JA Hilsmeier KA Fukuda Y Alam R. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 1994 149 339 44.
26. Linden M Svensson C Andersson E Andersson M Greiff L Persson CG. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5. Am J Respir Crit Care Med 2000 162 1705 8.
27. Sim TC Reece LM Hilsmeier KA Grant JA Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995 152 927 33.
28. Varney VA Jacobson MR Sudderick RM et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis 1992 146 170 6.
29. Greiff L Pipkorn U Alkner U Persson CGA. The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy 1990 20 253 9.
30. Prabhakar U Eirikis E Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Methods 2002 260 207 18.
31. Ossovskaya VS Bunnett NW. Protease-activated receptors contribution to physiology and disease. Physiol Rev 2004 84 579 621.
32. Molino M Barnathan ES Numerof R et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997 272 4043 9.
33. Bolton SJ McNulty CA Thomas RJ Hewitt CR Wardlaw AJ. Expression of and functional responses to protease-activated receptors on human eosinophils. J Leukoc Biol 2003 74 60 8.
34. Miike S McWilliam AS Kita H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J Immunol 2001 167 6615 22.